Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008.
Arhin
Francis F
FF
Moeck
Gregory
G
Draghi
Deborah C
DC
Pillar
Chris M
CM
Sahm
Daniel F
DF
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D005060:Europe; D006020:Glycopeptides / Q000494:pharmacology*; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology*; D006801:Humans; D000077427:Lipoglycopeptides; D008826:Microbial Sensitivity Tests; D017334:Teicoplanin / Q000494:pharmacology; D014640:Vancomycin / Q000494:pharmacology / Q000031:analogs & derivatives
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D017334:Teicoplanin; D014640:Vancomycin; C100708:oritavancin